AGP2 Antibody

AGP2 Targets and Biological Contexts

AGP2 nomenclature refers to distinct proteins depending on the organism:

Yeast Agp2 Studies

• Function: Agp2 in S. cerevisiae mediates uptake of L-carnitine, bleomycin-A5, and cycloheximide (CHX). Mutants lacking Agp2 exhibit drug resistance due to reduced uptake .

• Antibody Use: Polyclonal antibodies detect Agp2-GFP fusion proteins in immunoblotting, revealing CHX-induced degradation via ubiquitination .

Human AGAP2 in Cancer

• Role: AGAP2 promotes cancer cell invasion by activating phosphoinositide 3-kinase. Overexpression correlates with tumor aggressiveness .

• Antibodies: Commercial anti-AGAP2 antibodies (e.g., CSB-PA014480) are validated for ELISA, IHC, and WB, targeting isoforms ~24–45 kDa .

Diagnostic Use of Anti-GP2 Antibodies

• Crohn’s Disease (CD):

  • Specificity: aGP2 IgG/IgA distinguishes CD from intestinal tuberculosis (ITB) and Behçet’s disease (AUC: 0.78–0.82) .

  • Clinical Data:

    Parameter	aGP2 IgA (%)	aGP2 IgG (%)	ASCA IgA (%)	ASCA IgG (%)
    CD Sensitivity	33.9	42.7	34.5	45.6
    UC Prevalence	11.1	13.9	5.8	14.9

  • Association: aGP2 correlates with ileal involvement (L1) and penetrating disease (B3) in CD .

Key Products

• Validation: Antibodies are affinity-purified (>95% purity) and tested in species-specific assays .

Mechanistic Insights from AGP2 Studies

• Yeast Agp2 Degradation: CHX induces rapid ubiquitination and proteasomal degradation of Agp2, limiting drug uptake and upregulating efflux pumps like Pdr5 .

• Human AGAP2 Signaling: Binds nuclear PI3K to inhibit apoptosis, with isoforms (e.g., PIKE-L) enhancing cell survival in cancers .

Future Directions

• Therapeutic Targeting: AGAP2 inhibition may reduce cancer metastasis, while yeast Agp2 modulation could combat antifungal resistance.

• Diagnostic Refinement: aGP2 antibodies may improve IBD subtyping when combined with ASCA and pANCA .